Cancer J. 2019 Mar/Apr;25(2):100-105. doi: 10.1097/PPO.0000000000000361.
Reducing the rate of recurrence after curative-intent surgical resection is an attractive strategy for improving long-term survival in cancer. Perioperative therapies administered in the period immediately prior to, during, or after surgery therefore hold the potential to improve overall survival. Drug repurposing is a source of therapeutic candidates for further clinical investigation. We aimed to identify noncancer drugs with the potential to be repurposed as perioperative therapies.
The Repurposing Drugs in Oncology repurposing database and PubMed were used for a literature-based search of publications related to perioperative treatment of cancer. Three clinical trials registries were also searched to identify relevant clinical trials with survival endpoints. Both the literature and trial screens were supplemented with additional data known to the authors.
Fifty-two drugs were identified as potential perioperative therapies, with 67% having supporting human data. There are few clinical trials with survival endpoints, mainly in breast and colorectal cancers.
The perioperative setting is not as well established as the neoadjuvant and adjuvant settings, making identification of relevant research and clinical trials difficult. Despite the potential benefits of such interventions, there is a need for more well-designed clinical trials, additional research, and biomarkers of response.
降低根治性手术切除后的复发率是提高癌症患者长期生存率的一种有吸引力的策略。因此，在手术前、手术期间或手术后给予围手术期治疗有可能提高总体生存率。药物再利用是进一步临床研究的治疗候选药物的来源。我们旨在确定具有作为围手术期治疗药物再利用潜力的非癌症药物。
利用肿瘤再利用药物数据库和 PubMed 进行了基于文献的癌症围手术期治疗相关出版物的检索。还搜索了三个临床试验注册处，以确定具有生存终点的相关临床试验。文献和试验筛选均补充了作者已知的其他数据。
确定了 52 种潜在的围手术期治疗药物，其中 67%有支持人类数据。具有生存终点的临床试验很少，主要集中在乳腺癌和结直肠癌。
围手术期的治疗环境不如新辅助治疗和辅助治疗那样成熟，这使得相关研究和临床试验的识别变得困难。尽管这种干预有潜在的好处，但仍需要更多设计良好的临床试验、额外的研究以及反应的生物标志物。
